Abstract
Although scleroderma is generally considered a fibrosing disease of the tissues, it is now recognized that the underlying vascular disease is playing a fundamental role in its pathogenesis and associated tissue injury. The exact mechanism for the widespread scleroderma vascular disease is still unknown, but endothelial cell injury induced by infection, immune-mediated cytotoxicity, antiendothelial antibodies, and/or ischemia-reperfusion have all been implicated. The downstream effects of blood vessel perturbation produce “biomarkers” of vascular damage that reflect disease and may predict clinical outcomes. A complex interaction between endothelial cells, smooth muscle cells, extracellular matrix, and intravascular circulating factors is now recognized to contribute to the vascular reactivity, remodeling, and occlusive disease of scleroderma. Understanding the mechanisms underlying these processes provides rationale of novel therapeutic strategies and specific targeted therapy. This review will outline some of the evidence for the causes and consequences of scleroderma vascular disease.
Similar content being viewed by others
References
Norton WL, Nardo JM (1970) Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med 73:317–324
LeRoy EC (1996) Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22:675–694
Guiducci S, Giacomelli R, Cerinic MM (2007) Vascular complications of scleroderma. Autoimmun Rev 6:520–523
Suter LG, Murabito JM, Felson DT, Fraenkel L (2005) The incidence and natural history of Raynaud’s phenomenon in the community. Arthritis Rheum 52:1259–1263
Carpentier PH, Satger B, Poensin D, Maricq HR (2006) Incidence and natural history of Raynaud phenomenon: a long-term follow-up (14 years) of a random sample from the general population. J Vasc Surg 44:1023–1028
Korn JH, Mayes M, Matucci CM, Rainisio M, Pope J, Hachulla E et al (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985–3993
Gliddon AE, Dore CJ, Black CM, McHugh N, Moots R, Denton CP et al (2007) Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 56:3837–3846
Tiso F, Favaro M, Ciprian L, Cardarelli S, Rizzo M, Tonello M et al (2007) [Digital ulcers in a cohort of 333 scleroderma patients]. Reumatismo 59:215–220
Nihtyanova SI, Brough GM, Black CM, Denton CP (2008) Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 67:120–123
Hachulla E, Clerson P, Launay D, Lambert M, Morell-Dubois S, Queyrel V et al (2007) Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 34:2423–2430
Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ (1992) Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 35:688–693
Herrick AL, Oogarah PK, Freemont AJ, Marcuson R, Haeney M, Jayson MI (1994) Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation. Ann Rheum Dis 53:323–326
Matucci-Cerinic M, Seibold JR (2008) Digital ulcers and outcomes assessment in scleroderma. Rheumatology (Oxford) 47(Suppl 5):v46–v47
Ho M, Veale D, Eastmond C, Nuki G, Belch J (2000) Macrovascular disease and systemic sclerosis. Ann Rheum Dis 59:39–43
Stucker M, Quinna S, Memmel U, Rochling A, Traupe M, Hoffmann K et al (2000) Macroangiopathy of the upper extremities in progressive systemic sclerosis. Eur J Med Res 5:295–302
Hasegawa M, Nagai Y, Tamura A, Ishikawa O (2006) Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br J Dermatol 155:1159–1164
Rodnan GP, Myerowitz RL, Justh GO (1980) Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 59:393–408
Youssef P, Englert H, Bertouch J (1993) Large vessel occlusive disease associated with CREST syndrome and scleroderma. Ann Rheum Dis 52:464–466
Stafford L, Englert H, Gover J, Bertouch J (1998) Distribution of macrovascular disease in scleroderma. Ann Rheum Dis 57:476–479
Taylor MH, McFadden JA, Bolster MB, Silver RM (2002) Ulnar artery involvement in systemic sclerosis (scleroderma). J Rheumatol 29:102–106
Constans J, Germain C, Gosse P, Taillard J, Tiev K, Delevaux I et al (2007) Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS study. J Hypertens 25:1900–1906
Hettema ME, Zhang D, Stienstra Y, Oomen PN, Smit AJ, Kallenberg CG et al (2008) Decreased capillary permeability and capillary density in patients with systemic sclerosis using large-window sodium fluorescein videodensitometry of the ankle. Rheumatology (Oxford) 47:1409–1412
Sherer Y, Gerli R, Bocci EB, Gilburd B, Vaudo G, Bistoni O et al (2007) Heat-shock protein 65 autoantibodies are differently associated with early atherosclerosis in rheumatoid arthritis and in healthy subjects. Ann N Y Acad Sci 1108:408–413
Bartoli F, Angotti C, Fatini C, Conforti ML, Guiducci S, Blagojevic J et al (2007) Angiotensin-converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis. Rheumatology (Oxford) 46:772–775
Bartoli F, Blagojevic J, Bacci M, Fiori G, Tempestini A, Conforti ML et al (2007) Flow-mediated vasodilation and carotid intima-media thickness in systemic sclerosis. Ann N Y Acad Sci 1108:283–290
Szucs G, Timar O, Szekanecz Z, Der H, Kerekes G, Szamosi S et al (2007) Endothelial dysfunction precedes atherosclerosis in systemic sclerosis—relevance for prevention of vascular complications. Rheumatology (Oxford) 46:759–762
Bulkley BH, Roberts WC (1976) Atherosclerotic narrowing of the left main coronary artery. A necropsy analysis of 152 patients with fatal coronary heart disease and varying degrees of left main narrowing. Circulation 53:823–828
Bulkley BH, Klacsmann PG, Hutchins GM (1978) Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: a clinicopathologic study of 9 patients with progressive systemic sclerosis. Am Heart J 95:563–569
D’Angelo WA, Fries JF, Masi AT, Shulman LE (1969) Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 46:428–440
Akram MR, Handler CE, Williams M, Carulli MT, Andron M, Black CM et al (2006) Angiographically proven coronary artery disease in scleroderma. Rheumatology (Oxford) 45:1395–1398
Maricq HR, Downey JA, LeRoy EC (1976) Standstill of nailfold capillary blood flow during cooling in scleroderma and Raynaud’s syndrome. Blood Vessels 13:338–349
Maricq HR, LeRoy EC (1973) Patterns of finger capillary abnormalities in connective tissue disease by “wide-field” microscopy. Arthritis Rheum 16:619–628
Maricq HR, Weinberger AB, LeRoy EC (1982) Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy: a prospective study of patients with Raynaud’s phenomenon. J Rheumatol 9:289–291
Anderson ME, Allen PD, Moore T, Hillier V, Taylor CJ, Herrick AL (2005) Computerized nailfold video capillaroscopy—a new tool for assessment of Raynaud’s phenomenon. J Rheumatol 32:841–848
Wildt M, Hesselstrand R, Akesson A, Scheja A (2007) Simple counting of nailfold capillary density in suspected systemic sclerosis—9 years’ experience. Scand J Rheumatol 36:452–457
Maricq HR, LeRoy EC, D’Angelo WA, Medsger TA Jr, Rodnan GP, Sharp GC et al (1980) Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 23:183–189
Cutolo M, Pizzorni C, Sulli A (2004) Nailfold video-capillaroscopy in systemic sclerosis. Z Rheumatol 63:457–462
Harper FE, Maricq HR, Turner RE, Lidman RW, LeRoy EC (1982) A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report. Am J Med 72:883–888
Maricq HR, Harper FE, Khan MM, Tan EM, LeRoy EC (1983) Microvascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease. Clin Exp Rheumatol 1:195–205
Houtman PM, Kallenberg CG, Fidler V, Wouda AA (1986) Diagnostic significance of nailfold capillary patterns in patients with Raynaud’s phenomenon. An analysis of patterns discriminating patients with and without connective tissue disease. J Rheumatol 13:556–563
ter Borg EJ, Piersma-Wichers G, Smit AJ, Kallenberg CG, Wouda AA (1994) Serial nailfold capillary microscopy in primary Raynaud’s phenomenon and scleroderma. Semin Arthritis Rheum 24:40–47
Meli M, Gitzelmann G, Koppensteiner R, mann-Vesti BR (2006) Predictive value of nailfold capillaroscopy in patients with Raynaud’s phenomenon. Clin Rheumatol 25:153–158
Sulli A, Secchi ME, Pizzorni C, Cutolo M (2008) Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis 67:885–887
Grassi W, De AR (2007) Capillaroscopy: questions and answers. Clin Rheumatol 26:2009–2016
Di FM, Paradiso M, Riccieri V, Basili S, Mammarella A, Valesini G (2007) Autonomic dysfunction and microvascular damage in systemic sclerosis. Clin Rheumatol 26:1278–1283
Braverman IM, Ken-Yen A (1983) Ultrastructure and three-dimensional reconstruction of several macular and papular telangiectases. J Invest Dermatol 81:489–497
Walker JG, Stirling J, Beroukas D, Dharmapatni K, Haynes DR, Smith MD et al (2005) Histopathological and ultrastructural features of dermal telangiectasias in systemic sclerosis. Pathology 37:220–225
Kazandjian S, Bruneval P, Fiessinger JN, Camilleri JP, Housset E (1986) Active proliferation of telangiectases in skin of patients with progressive systemic sclerosis (PSS). Arch Dermatol Res 279:8–11
Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ et al (2000) Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu–Osler–Weber syndrome). Am J Med Genet 91:66–67
Mould TL, Roberts-Thomson PJ (2000) Pathogenesis of telangiectasia in scleroderma. Asian Pac J Allergy Immunol 18:195–200
McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE et al (1994) Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8:345–351
Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ et al (1996) Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13:189–195
Fujimoto M, Hasegawa M, Hamaguchi Y, Komura K, Matsushita T, Yanaba K et al (2006) A clue for telangiectasis in systemic sclerosis: elevated serum soluble endoglin levels in patients with the limited cutaneous form of the disease. Dermatology 213:88–92
Wipff J, Kahan A, Hachulla E, Sibilia J, Cabane J, Meyer O et al (2007) Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford) 46:622–625
Wipff J, Avouac J, Borderie D, Zerkak D, Lemarechal H, Kahan A et al (2008) Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology (Oxford) 47:972–975
Dharmapatni AA, Smith MD, Ahern MJ, Simpson A, Li C, Kumar S et al (2001) The TGF beta receptor endoglin in systemic sclerosis. Asian Pac J Allergy Immunol 19:275–282
Coffman JD, Cohen AS (1971) Total and capillary fingertip blood flow in Raynaud’s phenomenon. N Engl J Med 285:259–263
Traub YM, Shapiro AP, Rodnan GP, Medsger TA, McDonald RH Jr, Steen VD et al (1983) Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) 62:335–352
Cannon PJ, Hassar M, Case DB, Casarella WJ, Sommers SC, LeRoy EC (1974) The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine (Baltimore) 53:1–46
Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM et al (2007) Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 100:485–494
Follansbee WP, Curtiss EI, Medsger TA Jr, Steen VD, Uretsky BF, Owens GR et al (1984) Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med 310:142–148
Alexander EL, Firestein GS, Weiss JL, Heuser RR, Leitl G, Wagner HN Jr et al (1986) Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med 105:661–668
Young RH, Mark GJ (1978) Pulmonary vascular changes in scleroderma. Am J Med 64:998–1004
Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66:940–944
Sjogren RW (1994) Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 37:1265–1282
Sallam H, McNearney TA, Chen JD (2006) Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther 23:691–712
Nehra A, Hall SJ, Basile G, Bertero EB, Moreland R, Toselli P et al (1995) Systemic sclerosis and impotence: a clinicopathological correlation. J Urol 153:1140–1146
Lewis T (2008) The pathological changes in the arteries supplying the fingers in warm-handed people and in cases of so called Raynaud’s disease. Clin Sci (Lond) 3:287–319
Trostle DC, Bedetti CD, Steen VD, Al-Sabbagh MR, Zee B, Medsger TA Jr (1988) Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. Arthritis Rheum 31:393–400
Salerni R, Rodnan GP, Leon DF, Shaver JA (1977) Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 86:394–399
Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr (1986) Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 29:515–524
Al-Sabbagh MR, Steen VD, Zee BC, Nalesnik M, Trostle DC, Bedetti CD et al (1989) Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol 16:1038–1042
Yousem SA (1990) The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 21:467–474
Nagai Y, Yamanaka M, Hashimoto C, Nakano A, Hasegawa A, Tanaka Y et al (2007) Autopsy case of systemic sclerosis with severe pulmonary hypertension. J Dermatol 34:769–772
Cool CD, Kennedy D, Voelkel NF, Tuder RM (1997) Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 28:434–442
Roberts CG, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM (2006) A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut 55:1697–1703
Fleischmajer R, Perlish JS, Shaw KV, Pirozzi DJ (1976) Skin capillary changes in early systemic scleroderma. Electron microscopy and “in vitro” autoradiography with tritiated thymidine. Arch Dermatol 112:1553–1557
Trotta F, Biagini G, Cenacchi G, Ballardini G, Varotti C, Passarini B et al (1984) Microvascular changes in progressive systemic sclerosis: immunohistochemical and ultrastructural study. Clin Exp Rheumatol 2:209–215
Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166:255–263
Freemont AJ, Hoyland J, Fielding P, Hodson N, Jayson MI (1992) Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy. Br J Dermatol 126:561–568
Fleischmajer R, Perlish JS (1977) [3H]Thymidine labeling of dermal endothelial cells in scleroderma. J Invest Dermatol 69:379–382
Kazandjian S, Fiessinger JN, Camilleri JP, Dadoune JP, Housset E (1982) Endothelial cell renewal in skin of patients with progressive systemic sclerosis (PSS): an in vitro autoradiographic study. Acta Derm Venereol 62:425–429
Fleischmajer R, Perlish JS (1980) Capillary alterations in scleroderma. J Am Acad Dermatol 2:161–170
Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, Connolly MK et al (2008) Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS ONE 3:e1452
Hummers LK (2008) Biomarkers of vascular disease in scleroderma. Rheumatology (Oxford) 47(Suppl 5):v21–v22
Kahaleh MB, Osborn I, LeRoy EC (1981) Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud’s phenomenon. Ann Intern Med 94:482–484
James JP, Stevens TR, Hall ND, Maddison PJ, Goulding NJ, Silman A et al (1990) Factor VIII related antigen in connective tissue disease patients and relatives. Br J Rheumatol 29:6–9
Herrick AL, Barlow JD, Bowden A, Williams N, Hobson AR, Irving M et al (1996) Investigation of anal function in patients with systemic sclerosis. Ann Rheum Dis 55:370–374
Marasini B, Cugno M, Bassani C, Stanzani M, Bottasso B, Agostoni A (1992) Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud’s phenomenon. Int J Microcirc Clin Exp 11:375–382
Konttinen YT, Mackiewicz Z, Ruuttila P, Ceponis A, Sukura A, Povilenaite D et al (2003) Vascular damage and lack of angiogenesis in systemic sclerosis skin. Clin Rheumatol 22:196–202
Blann AD, Illingworth K, Jayson MI (1993) Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud’s phenomenon. J Rheumatol 20:1325–1330
Abraham D, Distler O (2007) How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 9(Suppl 2):S2
Silver RM (2008) Endothelin and scleroderma lung disease. Rheumatology (Oxford) 47(Suppl 5):v25–v26
Kahaleh MB (1991) Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 34:978–983
Yamane K, Miyauchi T, Suzuki N, Yuhara T, Akama T, Suzuki H et al (1992) Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 19:1566–1571
Sfikakis PP, McCune BK, Tsokos M, Aroni K, Vayiopoulos G, Tsokos GC (1993) Immunohistological demonstration of transforming growth factor-beta isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol 69:199–204
Yamane K (1994) Endothelin and collagen vascular disease: a review with special reference to Raynaud’s phenomenon and systemic sclerosis. Intern Med 33:579–582
Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R et al (1994) Circulating endothelin-1 levels in systemic sclerosis subsets—a marker of fibrosis or vascular dysfunction? J Rheumatol 21:1838–1844
Kadono T, Kikuchi K, Sato S, Soma Y, Tamaki K, Takehara K (1995) Elevated plasma endothelin levels in systemic sclerosis. Arch Dermatol Res 287:439–442
Denton CP, Bickerstaff MC, Shiwen X, Carulli MT, Haskard DO, Dubois RM et al (1995) Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 34:1048–1054
Tabata H, Yamakage A, Yamazaki S (1997) Cutaneous localization of endothelin-1 in patients with systemic sclerosis: immunoelectron microscopic study. Int J Dermatol 36:272–275
Silveri F, De AR, Poggi A, Muti S, Bonapace G, Argentati F et al (2001) Relative roles of endothelial cell damage and platelet activation in primary Raynaud’s phenomenon (RP) and RP secondary to systemic sclerosis. Scand J Rheumatol 30:290–296
Postlethwaite AE, Chiang TM (2007) Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 19:574–579
Kahaleh MB, Osborn I, LeRoy EC (1982) Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med 96:610–613
Kahaleh MB, Scharstein KK, LeRoy EC (1985) Enhanced platelet adhesion to collagen in scleroderma. Effect of scleroderma plasma and scleroderma platelets. J Rheumatol 12:468–471
Lima J, Fonollosa V, Fernandez-Cortijo J, Ordi J, Cuenca R, Khamashta MA et al (1991) Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis. J Rheumatol 18:1833–1836
Macko RF, Gelber AC, Young BA, Lowitt MH, White B, Wigley FM et al (2002) Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol 29:2565–2570
Reilly IA, Roy L, Fitzgerald GA (1986) Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud’s phenomenon. Br Med J (Clin Res Ed) 292:1037–1039
Pamuk GE, Turgut B, Pamuk ON, Vural O, Demir M, Cakir N (2007) Increased circulating platelet-leucocyte complexes in patients with primary Raynaud’s phenomenon and Raynaud’s phenomenon secondary to systemic sclerosis: a comparative study. Blood Coagul Fibrinolysis 18:297–302
Guiducci S, Distler JH, Jungel A, Huscher D, Huber LC, Michel BA et al (2008) The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. Arthritis Rheum 58:2845–2853
Gruschwitz M, von den DP, Kellner I, Hornstein OP, Sterry W (1992) Expression of adhesion proteins involved in cell–cell and cell–matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 27:169–177
Majewski S, Hunzelmann N, Johnson JP, Jung C, Mauch C, Ziegler-Heitbrock HW et al (1991) Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma. J Invest Dermatol 97:667–671
Kraling BM, Jimenez SA, Sorger T, Maul GG (1994) Isolation and characterization of microvascular endothelial cells from the adult human dermis and from skin biopsies of patients with systemic sclerosis. Lab Invest 71:745–754
Sollberg S, Peltonen J, Uitto J, Jimenez SA (1992) Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis Rheum 35:290–298
Gruschwitz MS, Hornstein OP, von den DP (1995) Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 38:184–189
Carson CW, Beall LD, Hunder GG, Johnson CM, Newman W (1993) Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J Rheumatol 20:809–814
Sondergaard K, Stengaard-Pedersen K, Zachariae H, Heickendorff L, Deleuran M, Deleuran B (1998) Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin. Br J Rheumatol 37:304–310
Ihn H, Sato S, Fujimoto M, Kikuchi K, Kadono T, Tamaki K et al (1997) Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. Br J Rheumatol 36:1270–1275
Kiener H, Graninger W, Machold K, Aringer M, Graninger WB (1994) Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Exp Rheumatol 12:483–487
Veale DJ, Kirk G, McLaren M, Belch JJ (1998) Clinical implications of soluble intercellular adhesion molecule-1 levels in systemic sclerosis. Br J Rheumatol 37:1227–1228
Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K (1998) Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol 37:1188–1192
Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Ciolkiewicz M (2006) A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis. Clin Rheumatol 25:314–319
Stratton RJ, Coghlan JG, Pearson JD, Burns A, Sweny P, Abraham DJ et al (1998) Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM 91:561–566
Mulligan-Kehoe MJ, Simons M (2007) Current concepts in normal and defective angiogenesis: implications for systemic sclerosis. Curr Rheumatol Rep 9:173–179
Mulligan-Kehoe MJ, Simons M (2008) Vascular disease in scleroderma: angiogenesis and vascular repair. Rheum Dis Clin North Am 34:73–79
Kahaleh MB, Sherer GK, LeRoy EC (1979) Endothelial injury in scleroderma. J Exp Med 149:1326–1335
Mulligan-Kehoe MJ, Drinane MC, Mollmark J, Casciola-Rosen L, Hummers LK, Hall A et al (2007) Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum 56:3448–3458
Marczak M, Majewski S, Skopinska-Rozewska E, Polakowski I, Jablonska S (1986) Enhanced angiogenic capability of monocyte-enriched mononuclear cell suspensions from patients with systemic scleroderma. J Invest Dermatol 86:355–358
Kahaleh MB, DeLustro F, Bock W, LeRoy EC (1986) Human monocyte modulation of endothelial cells and fibroblast growth: possible mechanism for fibrosis. Clin Immunol Immunopathol 39:242–255
Koch AE, Distler O (2007) Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 9(Suppl 2):S3
Giusti B, Fibbi G, Margheri F, Serrati S, Rossi L, Poggi F et al (2006) A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther 8:R115
Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM et al (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167–4171
Ribatti D, Cantatore FP, Vacca A, D’Amore M, Ria R, Roncali L et al (1998) Systemic sclerosis stimulates angiogenesis in the chick embryo chorioallantoic membrane. Clin Rheumatol 17:115–120
Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S et al (2002) Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4:R11
Davies CA, Jeziorska M, Freemont AJ, Herrick AL (2006) The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 37:190–197
Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J et al (2004) Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95:109–116
Qazi U, Lam C, Karumanchi SA, Petri M (2008) Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. J Rheumatol 35:631–634
Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B (2000) Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 43:889–893
Dziankowska-Bartkowiak B, Waszczykowska E, Dziankowska-Zaboroszczyk E, de Graft-Johnson JE, Zalewska A, Luczynska M et al (2006) Decreased ratio of circulatory vascular endothelial growth factor to endostatin in patients with systemic sclerosis—association with pulmonary involvement. Clin Exp Rheumatol 24:508–513
Dziankowska-Bartkowiak B, Waszczykowska E, Zalewska A, Sysa-Jedrzejowska A (2005) Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients. Mediators Inflamm 2005:144–149
Hummers LK, Hall A, Wigley F, Simons M (2004) Evidence for abnormal angiogenesis in scleroderma patients. Arthritis Rheum 50:S630
D’Alessio S, Fibbi G, Cinelli M, Guiducci S, Del RA, Margheri F et al (2004) Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 50:3275–3285
Del RA, Distler O, Milia AF, Emanueli C, Ibba-Manneschi L, Guiducci S et al (2005) Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement. Ann Rheum Dis 64:382–387
Giusti B, Serrati S, Margheri F, Papucci L, Rossi L, Poggi F et al (2005) The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum 52:3618–3628
Distler JH, Gay S, Distler O (2006) Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford) 45(Suppl 3):iii26–iii27
Gomer RH (2008) Circulating progenitor cells and scleroderma. Curr Rheumatol Rep 10:183–188
Del PN, Colombo G, Fracchiolla N, Moronetti LM, Ingegnoli F, Maglione W et al (2004) Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 50:1296–1304
Allanore Y, Batteux F, Avouac J, Assous N, Weill B, Kahan A (2007) Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol 25:60–66
Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y (2004) Defective vasculogenesis in systemic sclerosis. Lancet 364:603–610
Del Papa N, Quirici N, Soligo D, Scavullo C, Cortiana M, Borsotti C et al (2006) Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 54:2605–2615
Cipriani P, Guiducci S, Miniati I, Cinelli M, Urbani S, Marrelli A et al (2007) Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 56:1994–2004
Kuwana M, Kaburaki J, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y (2006) Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum 54:1946–1951
Furukawa S, Yasuda S, Amengual O, Horita T, Atsumi T, Koike T (2006) Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann Rheum Dis 65:1118–1120
Gurevich VS (2005) Influenza, autoimmunity and atherogenesis. Autoimmun Rev 4:101–105
Derk CT, Jimenez SA (2006) Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? Autoimmun Rev 5:25–32
Abou-Raya A, Abou-Raya S, Helmii M (2008) Statins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers. J Rheumatol 35:1801–1808
Freedman RR, Girgis R, Mayes MD (1999) Endothelial and adrenergic dysfunction in Raynaud’s phenomenon and scleroderma. J Rheumatol 26:2386–2388
Freedman RR, Girgis R, Mayes MD (2001) Abnormal responses to endothelial agonists in Raynaud’s phenomenon and scleroderma. J Rheumatol 28:119–121
Freedman RR, Girgis R, Mayes MD (1999) Acute effect of nitric oxide on Raynaud’s phenomenon in scleroderma. Lancet 354:739
Andersen GN, Caidahl K, Kazzam E, Petersson AS, Waldenstrom A, Mincheva-Nilsson L et al (2000) Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 43:1085–1093
Cotton SA, Herrick AL, Jayson MI, Freemont AJ (1999) Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol 189:273–278
Yamamoto T, Katayama I, Nishioka K (1998) Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 25:314–317
Dooley A, Gao B, Bradley N, Abraham DJ, Black CM, Jacobs M et al (2006) Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford) 45:676–684
Mok MY, Fung PC, Ooi C, Tse HF, Wong Y, Lam YM et al (2008) Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis. Clin Rheumatol 27:315–322
Romero LI, Zhang DN, Cooke JP, Ho HK, Avalos E, Herrera R et al (2000) Differential expression of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma. Vasc Med 5:147–158
Kharitonov SA, Cailes JB, Black CM, du Bois RM, Barnes PJ (1997) Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 52:1051–1055
Fajac I, Kahan A, Menkes CJ, Dessanges JF, l’Ava-Santucci J, nh-Xuan AT (1998) Increased nitric oxide in exhaled air in patients with systemic sclerosis. Clin Exp Rheumatol 16:547–552
Paredi P, Kharitonov SA, Loukides S, Pantelidis P, du Bois RM, Barnes PJ (1999) Exhaled nitric oxide is increased in active fibrosing alveolitis. Chest 115:1352–1356
Shimizu K, Ogawa F, Muroi E, Hara T, Komura K, Bae SJ et al (2007) Increased serum levels of nitrotyrosine, a marker for peroxynitrite production, in systemic sclerosis. Clin Exp Rheumatol 25:281–286
Stein CM, Tanner SB, Awad JA, Roberts LJ, Morrow JD (1996) Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 39:1146–1150
Bruckdorfer KR, Hillary JB, Bunce T, Vancheeswaran R, Black CM (1995) Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 38:1060–1067
Herrick AL, Matucci CM (2001) The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 19:4–8
Ruiz-Ortega M, Ruperez M, Esteban V, Egido J (2003) Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 5:73–79
Cohn RD, van EC, Habashi JP, Soleimani AA, Klein EC, Lisi MT et al (2007) Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13:204–210
Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC III (2008) Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N Engl J Med 358:2787–2795
Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M (2005) Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 111:2509–2517
Orfanos SE, Psevdi E, Stratigis N, Langleben D, Catravas JD, Kyriakidis M et al (2001) Pulmonary capillary endothelial dysfunction in early systemic sclerosis. Arthritis Rheum 44:902–911
Langleben D, Orfanos SE, Giovinazzo M, Hirsch A, Baron M, Senecal JL et al (2008) Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. Arthritis Rheum 58:1156–1164
Fatini C, Gensini F, Sticchi E, Battaglini B, Angotti C, Conforti ML et al (2002) High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. Am J Med 112:540–544
Pignone A, Rosso AD, Brosnihan KB, Perfetto F, Livi R, Fiori G et al (2007) Reduced circulating levels of angiotensin-(1-7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control. Ann Rheum Dis 66:1305–1310
Herrick AL (2000) Vascular function in systemic sclerosis. Curr Opin Rheumatol 12:527–533
Murray AK, Moore TL, King TA, Herrick AL (2006) Abnormal microvascular response is localized to the digits in patients with systemic sclerosis. Arthritis Rheum 54:1952–1960
Albrecht HP, Hiller D, Hornstein OP, Buhler-Singer S, Muck M, Gruschwitz M (1993) Microcirculatory functions in systemic sclerosis: additional parameters for therapeutic concepts? J Invest Dermatol 101:211–215
Roustit M, Simmons GH, Carpentier P, Cracowski JL (2008) Abnormal digital neurovascular response to local heating in systemic sclerosis. Rheumatology (Oxford) 47:860–864
Lekakis J, Mavrikakis M, Papamichael C, Papazoglou S, Economou O, Scotiniotis I et al (1998) Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud’s phenomenon. Am Heart J 136:905–912
Khan F, Belch JJ (1999) Skin blood flow in patients with systemic sclerosis and Raynaud’s phenomenon: effects of oral l-arginine supplementation. J Rheumatol 26:2389–2394
Gunawardena H, Harris ND, Carmichael C, McHugh NJ (2007) Microvascular responses following digital thermal hyperaemia and iontophoresis measured by laser Doppler imaging in idiopathic inflammatory myopathy. Rheumatology (Oxford) 46:1483–1486
Rossi M, Bazzichi L, Di MC, Franzoni F, Raimo K, Della RA et al (2008) Blunted increase of digital skin vasomotion following acetylcholine and sodium nitroprusside iontophoresis in systemic sclerosis patients. Rheumatology (Oxford) 47:1012–1017
Furspan PB, Chatterjee S, Freedman RR (2004) Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud’s disease. Arthritis Rheum 50:1578–1585
Flavahan NA (2008) Regulation of vascular reactivity in scleroderma: new insights into Raynaud’s phenomenon. Rheum Dis Clin North Am 34:81–87
Flavahan NA, Flavahan S, Liu Q, Wu S, Tidmore W, Wiener CM et al (2000) Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 43:1886–1890
Generini S, Matucci CM (1999) Raynaud’s phenomenon and vascular disease in systemic sclerosis. Adv Exp Med Biol 455:93–100
Generini S, Seibold JR, Matucci-Cerinic M (2005) Estrogens and neuropeptides in Raynaud’s phenomenon. Rheum Dis Clin North Am 31:177–1xi
Milner P, Bodin P, Guiducci S, Del RA, Kahaleh MB, Matucci-Cerinic M et al (2004) Regulation of substance P mRNA expression in human dermal microvascular endothelial cells. Clin Exp Rheumatol 22:S24–S27
Bunker CB, Terenghi G, Springall DR, Polak JM, Dowd PM (1990) Deficiency of calcitonin gene-related peptide in Raynaud’s phenomenon. Lancet 336:1530–1533
Brain SD, Petty RG, Lewis JD, Williams TJ (1990) Cutaneous blood flow responses in the forearms of Raynaud’s patients induced by local cooling and intradermal injections of CGRP and histamine. Br J Clin Pharmacol 30:853–859
Bunker CB, Reavley C, O’Shaughnessy DJ, Dowd PM (1993) Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud’s phenomenon. Lancet 342:80–83
Lekakis J, Papamichael C, Mavrikakis M, Voutsas A, Stamatelopoulos S (1998) Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud’s phenomenon secondary to systemic sclerosis. Am J Cardiol 82:1555–1557, A8
Fraenkel L, Zhang Y, Chaisson CE, Evans SR, Wilson PW, Felson DT (1998) The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. Ann Intern Med 129:208–211
Wigley FM (2001) Raynaud’s phenomenon is linked to unopposed estrogen replacement therapy in postmenopausal women. Clin Exp Rheumatol 19:10–11
Mizutani H, Hayashi T, Nouchi N, Inachi S, Suzuki K, Shimizu M (1996) Increased endothelial and epidermal thrombomodulin expression and plasma thrombomodulin level in progressive systemic sclerosis. Acta Med Okayama 50:293–297
Salojin KV, Le Tonqueze M, Saraux A, Nassonov EL, Dueymes M, Piette JC et al (1997) Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med 102:178–185
Kahaleh B (2008) Vascular disease in scleroderma: mechanisms of vascular injury. Rheum Dis Clin North Am 34:57–71
Shanahan WR Jr, Korn JH (1982) Cytotoxic activity of sera from scleroderma and other connective tissue diseases. Lack of cellular and disease specificity. Arthritis Rheum 25:1391–1395
Meyer O, Haim T, Dryll A, Lansaman J, Ryckewaert A (1983) Vascular endothelial cell injury in progressive systemic sclerosis and other connective tissue diseases. Clin Exp Rheumatol 1:29–34
Drenk F, Mensing H, Serbin A, Deicher H (1985) Studies on endothelial cell cytotoxic activity in sera of patients with progressive systemic sclerosis, Raynaud syndrome, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int 5:259–263
Cohen S, Johnson AR, Hurd E (1983) Cytotoxicity of sera from patients with scleroderma. Effects on human endothelial cells and fibroblasts in culture. Arthritis Rheum 26:170–178
Kahaleh MB, LeRoy EC (1983) Endothelial injury in scleroderma. A protease mechanism. J Lab Clin Med 101:553–560
Kahaleh MB, Fan PS (1997) Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. Clin Immunol Immunopathol 83:32–40
Penning CA, Cunningham J, French MA, Harrison G, Rowell NR, Hughes P (1984) Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic sclerosis. Clin Exp Immunol 57:548–556
Rosenbaum J, Pottinger BE, Woo P, Black CM, Loizou S, Byron MA et al (1988) Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol 72:450–456
Holt CM, Lindsey N, Moult J, Malia RG, Greaves M, Hume A et al (1989) Antibody-dependent cellular cytotoxicity of vascular endothelium: characterization and pathogenic associations in systemic sclerosis. Clin Exp Immunol 78:359–365
Carvalho D, Savage CO, Black CM, Pearson JD (1996) IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 97:111–119
Tan EM, Pearson CM (1972) Rheumatic disease sera reactive with capillaries in the mouse kidney. Arthritis Rheum 15:23–28
Hill MB, Phipps JL, Cartwright RJ, Milford WA, Greaves M, Hughes P (1996) Antibodies to membranes of endothelial cells and fibroblasts in scleroderma. Clin Exp Immunol 106:491–497
Ihn H, Sato S, Fujimoto M, Igarashi A, Yazawa N, Kubo M et al (2000) Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol 119:203–209
Negi VS, Tripathy NK, Misra R, Nityanand S (1998) Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 25:462–466
Pignone A, Scaletti C, Matucci-Cerinic M, Vazquez-Abad D, Meroni PL, Del Papa N et al (1998) Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 16:527–532
Magro CM, Ross P, Marsh CB, Allen JN, Liff D, Knight DA et al (2007) The role of anti-endothelial cell antibody-mediated microvascular injury in the evolution of pulmonary fibrosis in the setting of collagen vascular disease. Am J Clin Pathol 127:237–247
Renaudineau Y, Revelen R, Levy Y, Salojin K, Gilburg B, Shoenfeld Y et al (1999) Anti-endothelial cell antibodies in systemic sclerosis. Clin Diagn Lab Immunol 6:156–160
Bordron A, Dueymes M, Levy Y, Jamin C, Leroy JP, Piette JC et al (1998) The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 101:2029–2035
Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98:785–792
Nguyen VA, Sgonc R, Dietrich H, Wick G (2000) Endothelial injury in internal organs of University of California at Davis line 200 (UCD 200) chickens, an animal model for systemic sclerosis (Scleroderma). J Autoimmun 14:143–149
Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G (2000) Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43:2550–2562
Laplante P, Raymond MA, Gagnon G, Vigneault N, Sasseville AM, Langelier Y et al (2005) Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis. J Immunol 174:5740–5749
Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ (1992) Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 35:688–693
Servettaz A, Tamby MC, Guilpain P, Reinbolt J, Garcia de la Pena-Lefebvre, Allanore Y et al (2006) Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B). Clin Immunol 120:212–219
Wusirika R, Ferri C, Marin M, Knight DA, Waldman WJ, Ross P Jr et al (2003) The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. Am J Clin Pathol 120:596–606
Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M et al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354:2667–2676
Balada E, Simeon-Aznar CP, Ordi-Ros J, Rosa-Leyva M, Selva-O’Callaghan A, Pardos-Gea J et al (2008) Anti-PDGFR-alpha antibodies measured by non-bioactivity assays are not specific for systemic sclerosis. Ann Rheum Dis 67:1027–1029
Loizos N, Weiner J, Griffin H, Boin F, Hummers LK, Wigley FM et al (2008) Lack of evidence for agonist activity by auto-antibodies to platelet-derived growth factor (PDGF) receptor alpha in systemic sclerosis (scleroderma). Arthritis Rheum 58:S927
Kahaleh MB, LeRoy EC (1999) Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 31:195–214
Kahaleh B (2008) The microvascular endothelium in scleroderma. Rheumatology (Oxford) 47(Suppl 5):v14–v15
Lunardi C, Bason C, Navone R, Millo E, Damonte G, Corrocher R et al (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 6:1183–1186
Marks RM, Czerniecki M, Andrews BS, Penny R (1988) The effects of scleroderma serum on human microvascular endothelial cells. Induction of antibody-dependent cellular cytotoxicity. Arthritis Rheum 31:1524–1534
Majewski S, Blaszczyk M, Jablonska S, Rudnicka L, Wasik M, Skiendzielewska A et al (1990) Cytotoxic effects of sera from patients with systemic scleroderma: comparison of three different in vitro methods. Rheumatol Int 10:65–70
Rudnicka L, Majewski S, Blaszczyk M, Skiendzielewska A, Makiela B, Skopinska M et al (1992) Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma). Arthritis Rheum 35:771–775
Komura K, Sato S, Hasegawa M, Fujimoto M, Takehara K (2004) Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol 31:514–519
Venneker GT, van den Hoogen FH, Boerbooms AM, Bos JD, Asghar SS (1994) Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage. Lab Invest 70:830–835
Sprott H, Muller-Ladner U, Distler O, Gay RE, Barnum SR, Landthaler M et al (2000) Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma). J Rheumatol 27:402–404
Helmbold P, Fiedler E, Fischer M, Marsch WC (2004) Hyperplasia of dermal microvascular pericytes in scleroderma. J Cutan Pathol 31:431–440
Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM (1999) Activation of microvascular pericytes in autoimmune Raynaud’s phenomenon and systemic sclerosis. Arthritis Rheum 42:930–941
Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ (2005) Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 7:R1113–R1123
Postlethwaite AE, Shigemitsu H, Kanangat S (2004) Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 16:733–738
Denton CP, Xu S, Welsh KI, Pearson JD, Black CM (1996) Scleroderma fibroblast phenotype is modulated by endothelial cell co-culture. J Rheumatol 23:633–638
Denton CP, Shi-Wen X, Sutton A, Abraham DJ, Black CM, Pearson JD (1998) Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol 114:293–300
Gruschwitz MS, Vieth G (1997) Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. Arthritis Rheum 40:540–550
Faller DV (1999) Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol 26:74–84
Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE et al (2007) Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56:311–322
Hong KH, Yoo SA, Kang SS, Choi JJ, Kim WU, Cho CS (2006) Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts. Clin Exp Immunol 146:362–370
Gabrielli A, Svegliati S, Moroncini G, Pomponio G, Santillo M, Avvedimento EV (2008) Oxidative stress and the pathogenesis of scleroderma: the Murrell’s hypothesis revisited. Semin Immunopathol 30:329–337
Klareskog L, Gustafsson R, Scheynius A, Hallgren R (1990) Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 33:1534–1541
Zheng XY, Zhang JZ, Tu P, Ma SQ (1998) Expression of platelet-derived growth factor B-chain and platelet-derived growth factor beta-receptor in fibroblasts of scleroderma. J Dermatol Sci 18:90–97
Casciola-Rosen L, Wigley F, Rosen A (1997) Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 185:71–79
Herrick AL, Worthington H, Rieley F, Clarke D, Schofield D, Braganza JM et al (1996) Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. J Rheumatol 23:650–653
Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI (1994) Micronutrient antioxidant status in patients with primary Raynaud’s phenomenon and systemic sclerosis. J Rheumatol 21:1477–1483
Blake DR, Winyard P, Scott DG, Brailsford S, Blann A, Lunec J (1985) Endothelial cell cytotoxicity in inflammatory vascular diseases—the possible role of oxidised lipoproteins. Ann Rheum Dis 44:176–182
Tikly M, Channa K, Theodorou P, Gulumian M (2006) Lipid peroxidation and trace elements in systemic sclerosis. Clin Rheumatol 25:320–324
Whittaker R, Barnett A, Ryan P (1993) Antiphospholipid syndrome in scleroderma. J Rheumatol 20:1598–1600
Chun WH, Bang D, Lee SK (1996) Antiphospholipid syndrome associated with progressive systemic sclerosis. J Dermatol 23:347–351
Zandman-Goddard G, Tweezer-Zaks N, Shalev T, Levy Y, Ehrenfeld M, Langevitz P (2007) A novel overlap syndrome: systemic sclerosis associated with antiphospholipid syndrome—a case series. Ann N Y Acad Sci 1108:497–504
Bamberga P, Asero R, Vismara A, Brucato A, Riboldi P, Meroni PL (1987) Anti-cardiolipin antibodies in progressive systemic sclerosis (PSS). Clin Exp Rheumatol 5:387–388
Katayama I, Otoyama K, Kondo S, Nishioka K, Nishiyama S (1990) Clinical manifestations in anticardiolipin antibody-positive patients with progressive systemic sclerosis. J Am Acad Dermatol 23:198–201
Speranskii AI, Riazantseva TA, Guseva NG, Melkumova KL, Ivanova SM (1990) [Anti-cardiolipin antibodies and other immunological disorders in patients with systemic scleroderma]. Revmatologiia (Mosk) 3:11–14
Picillo U, Migliaresi S, Marcialis MR, Ferruzzi AM, Tirri G (1995) Clinical significance of anticardiolipin antibodies in patients with systemic sclerosis. Autoimmunity 20:1–7
Merkel PA, Chang Y, Pierangeli SS, Convery K, Harris EN, Polisson RP (1996) The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 101:576–583
Sulik A, Kowal-Bielecka O, Domyslawska I, Chwiecko J, Sierakowski S (2005) The prevalence and clinical significance of antiphospholipid antibodies in the patients with systemic sclerosis—preliminary report. Rocz Akad Med Bialymst 50 Suppl 1:228–231
Pope JE, Thompson A (2000) The frequency and significance of anticardiolipin antibodies in scleroderma. J Rheumatol 27:1450–1452
Marai I, Gilburd B, Blank M, Shoenfeld Y (2003) Anti-cardiolipin and anti-beta2-glycoprotein I (beta2GP-I) antibody assays as screening for anti-phospholipid syndrome. Hum Antibodies 12:57–62
Enzenauer RJ, Collier DH, Lopez LR (2006) Anticardiolipin antibodies in scleroderma. J Clin Rheumatol 12:324–326
Malia RG, Greaves M, Rowlands LM, Lawrence AC, Hume A, Rowell NR et al (1988) Anticardiolipin antibodies in systemic sclerosis: immunological and clinical associations. Clin Exp Immunol 73:456–460
Assous N, Allanore Y, Batteux F, Meune C, Toulon P, Weill B et al (2005) Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol 23:199–204
Herrick AL, Oogarah PK, Freemont AJ, Marcuson R, Haeney M, Jayson MI (1994) Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation. Ann Rheum Dis 53:323–326
Marie I, Jouen F, Hellot MF, Levesque H (2008) Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis. Br J Dermatol 158:141–144
Boin F, Johnson E, Rosen A, Wigley F, Casciola-Rosen L (2008) Anti-beta2 Glycoprotein I antibodies are independently associated with macrovascular disease and mortality in Scleroderma Patients. Arthritis Rheum 58:S946–S947
Harigai M, Hara M, Nakazawa S, Fukasawa C, Ohta S, Sugiura T et al (1999) Ligation of CD40 induced tumor necrosis factor-alpha in rheumatoid arthritis: a novel mechanism of activation of synoviocytes. J Rheumatol 26:1035–1043
Matucci-Cerinic M, Lotti T, Lombardi A, Pignone A, Iannone F, Beneforti E et al (1990) Cutaneous and plasma fibrinolytic activity in systemic sclerosis. Evidence of normal plasminogen activation. Int J Dermatol 29:644–648
Munkvad S, Gram J, Jespersen J (1989) Depressed plasma fibrinolytic activity in a group of patients with connective tissue diseases. Scand J Rheumatol 18:277–282
Cerinic MM, Valentini G, Sorano GG, D’Angelo S, Cuomo G, Fenu L et al (2003) Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 32:285–295
Ames PR, Lupoli S, Alves J, Atsumi T, Edwards C, Iannaccone L et al (1997) The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome. Br J Rheumatol 36:1045–1050
Thompson AE, Shea B, Welch V, Fenlon D, Pope JE (2001) Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum 44:1841–1847
Allanore Y, Borderie D, Perianin A, Lemarechal H, Ekindjian OG, Kahan A (2005) Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis. Arthritis Res Ther 7:R93–100
Sunkel CE, Fau dC-J, Cillero FJ, Priego JG, Ortega MP (1988) Synthesis, platelet aggregation inhibitory activity, and in vivo antithrombotic activity of new 1,4-dihydropyridines. J Med Chem 31:1886–1890
Mason RP (1999) Effects of calcium channel blockers on cellular apoptosis: implications for carcinogenic potential. Cancer 85:2093–2102
Morris JL, Gibbins IL, Kadowitz PJ, Herzog H, Kreulen DL, Toda N et al (1995) Roles of peptides and other substances in cotransmission from vascular autonomic and sensory neurons. Can J Physiol Pharmacol 73:521–532
Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Prazosin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev:CD000956
Chotani MA, Flavahan S, Mitra S, Daunt D, Flavahan NA (2000) Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 278:H1075–H1083
Bailey SR, Mitra S, Flavahan S, Flavahan NA (2005) Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. Am J Physiol Heart Circ Physiol 289:H243–H250
Bailey SR, Eid AH, Mitra S, Flavahan S, Flavahan NA (2004) Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation. Circ Res 94:1367–1374
Akhmetshina A, Dees C, Pileckyte M, Szucs G, Spriewald BM, Zwerina J et al (2008) Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 58:2553–2564
Wise RA, Wigley FM, White B, Leatherman G, Zhong J, Krasa H et al (2004) Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 50:3994–4001
Coffman JD, Clement DL, Creager MA, Dormandy JA, Janssens MM, McKendry RJ et al (1989) International study of ketanserin in Raynaud’s phenomenon. Am J Med 87:264–268
Seibold JR, Jageneau AH (1984) Treatment of Raynaud’s phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor. Arthritis Rheum 27:139–146
Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Ketanserin for Raynaud’s phenomenon in Progressive Systemic Sclerosis. Cochrane Database Syst Rev 2:CD000954
Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM (2003) Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 42:601–602
Giannattasio C, Pozzi M, Gardinali M, Montemerlo E, Citterio F, Maestroni S et al (2007) Effects of prostaglandin E1alpha cyclodextrin [corrected] treatment on endothelial dysfunction in patients with systemic sclerosis. J Hypertens 25:793–797
Winkelmann RK, Goldyne ME, Linscheid RL (1976) Hypersensitivity of scleroderma cutaneous vascular smooth muscle to 5-hydroxytryptamine. Br J Dermatol 95:51–56
Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E et al (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud’s phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19:503–508
Chung L, Fiorentino D (2006) A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. J Am Acad Dermatol 54:880–882
Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr et al (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120:199–206
Badesch DB, McLaughlin VV, Delcroix M, Vizza CD, Olschewski H, Sitbon O et al (2004) Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 43:56S–61S
Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM et al (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132:425–434
Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A et al (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496–1502
Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ et al (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322–329
Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T et al (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108:241–250
Ikeda D, Tsujino I, Sakaue S, Ohira H, Itoh N, Kamigaki M et al (2007) Pilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension. Circ J 71:1829–1831
Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L et al (2003) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41:2119–2125
Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF et al (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358:1119–1123
Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903
Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ (2007) Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 26:63–69
Cheng JW (2008) Ambrisentan for the management of pulmonary arterial hypertension. Clin Ther 30:825–833
Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P et al (2007) Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 56:1985–1993
Jain M, Varga J (2006) Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers. Expert Opin Pharmacother 7:1487–1501
Proietti M, Aversa A, Letizia C, Rossi C, Menghi G, Bruzziches R et al (2007) Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels. J Rheumatol 34:1712–1717
Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galie N et al (2007) Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 34:2417–2422
Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK et al (2002) Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 71:398–402
Fries R, Shariat K, von WH, Bohm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985
Anderson ME, Moore TL, Hollis S, Jayson MI, King TA, Herrick AL (2002) Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud’s phenomenon and systemic sclerosis. Rheumatology (Oxford) 41:324–328
Teh LS, Manning J, Moore T, Tully MP, O’Reilly D, Jayson MI (1995) Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenon. Br J Rheumatol 34:636–641
Chung L, Baron M, Collier DH, Csuka ME, Fiorentino D, Gruber B et al (2007) A multi-center placebo-controlled “In-Life” study of MQX-503 in patients with Raynaud phenomenon. Arthritis Rheum 56:S824
Fleming JN, Schwartz SM (2008) The pathology of scleroderma vascular disease. Rheum Dis Clin North Am 34:41–55
Agewall S, Hernberg A (2006) Atorvastatin normalizes endothelial function in healthy smokers. Clin Sci (Lond) 111:87–91
Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI (2007) Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 46:1560–1565
Iida K, Goland S, Akima T, Luo H, Birnbaum Y, Siegel RJ (2007) Effect of a single 20-mg tablet of Atorvastatin on brachial artery blood flow in normolipidemic male smokers versus nonsmokers. Am J Cardiol 100:881–884
Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E et al (1999) Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 42:2646–2655
Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH et al (2004) Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114:1308–1316
Barst RJ (2005) PDGF signaling in pulmonary arterial hypertension. J Clin Invest 115:2691–2694
Ghofrani HA, Seeger W, Grimminger F (2005) Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353:1412–1413
van der MJ, Wouda AA, Kallenberg CG, Wesseling H (1987) A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud’s phenomenon. Vasa Suppl 18:71–75
Beckett VL, Conn DL, Fuster V, Osmundson PJ, Strong CG, Chao EY et al (1984) Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. Arthritis Rheum 27:1137–1143
Denton CP, Howell K, Stratton RJ, Black CM (2000) Long-term low molecular weight heparin therapy for severe Raynaud’s phenomenon: a pilot study. Clin Exp Rheumatol 18:499–502
Goldberg J, Dlesk A (1986) Successful treatment of Raynaud’s phenomenon with pentoxifylline. Arthritis Rheum 29:1055–1056
Goodfield MJ, Rowell NR (1989) Treatment of peripheral gangrene due to systemic sclerosis with intravenous pentoxifylline. Clin Exp Dermatol 14:161–162
Dean SM, Satiani B (2001) Three cases of digital ischemia successfully treated with cilostazol. Vasc Med 6:245–248
Denton CP, Bunce TD, Dorado MB, Roberts Z, Wilson H, Howell K et al (1999) Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud’s phenomenon. Rheumatology (Oxford) 38:309–315
Sambo P, Amico D, Giacomelli R, Matucci-Cerinic M, Salsano F, Valentini G et al (2001) Intravenous N-acetylcysteine for treatment of Raynaud’s phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 28:2257–2262
Herrick AL, Hollis S, Schofield D, Rieley F, Blann A, Griffin K et al (2000) A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 18:349–356
Sycha T, Graninger M, Auff E, Schnider P (2004) Botulinum toxin in the treatment of Raynaud’s phenomenon: a pilot study. Eur J Clin Invest 34:312–313
Acknowledgments
The author thanks the Scleroderma Research Foundation and the Board members of the Johns Hopkins Scleroderma Center, for their support of our research program, and Pam Hill and Jolene Patey for their help in the preparation of this manuscript. The author is grateful for the wonderful friendship and inspiration given by Dr Ronald Asherson over the years.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wigley, F.M. Vascular Disease in Scleroderma. Clinic Rev Allerg Immunol 36, 150–175 (2009). https://doi.org/10.1007/s12016-008-8106-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-008-8106-x